Clinically, PDE-4 inhibitors, such as apremilast, have shown efficacy in reducing plaque severity and improving patient outcomes, though their benefits are often partial, indicating the need for combination therapies to address the multifaceted inflammatory milieu of psoriasis (119). This evidence concerns the gene PDE4A and psoriasis.